We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Envista Stock Up 42.5% in a Year: What's Driving It?
Read MoreHide Full Article
Key Takeaways
NVST stock surged 42.5% in a year, beating industry decline and S&P 500 gains.
Envista growth is driven by acquisitions, R&D investment, and global expansion, including China.
NVST maintains strong balance sheet with zero current debt and $1.21B cash.
Envista (NVST - Free Report) shares have climbed 42.5% over the past year, showcasing impressive momentum. The stock has outpaced the industry’s 22.5% decline and the S&P 500 composite’s 16.6% gain.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #1 (Strong Buy) company appears to be a solid wealth creator for its investors now.
Headquartered in Brea, CA, Envista was built through the acquisition and integration of more than 25 leading dental businesses and brands over a 15-year period. The company is a global family of more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr. The company offers a comprehensive solution to support implant-based tooth replacements, orthodontic treatments, digital imaging and diagnostics. Envista operates through two segments — Specialty Products & Technologies and Equipment & Consumables.
Key Factors Behind NVST’s Surge
Envista’s share price is trending upward, prompted by strategic acquisitions which complement its current portfolio and broaden it into new and lucrative economic sectors. In line with this, in the first half of 2025, the company closed two small acquisitions, both at favourable EBITDA multiples, which supported its ongoing organic initiatives.
Investors expressed optimism about Envista’s priorities, centered on three areas — growth, operations and people. The fourth quarter of 2025 delivered positive growth across key businesses and all major geographies, supported by a double-digit increase in R&D investment. The company also hosted several high-impact events across geographies and business segments. Envista continues to benefit from the Envista Business System (“EBS”). In 2025, Envista reduced company-wide G&A expenses by 10% year over year, while maintaining its high standards of safety, quality and customer service.
The company also expanded its manufacturing footprint in China with a new site in Suzhou, primarily to support growing local demand. Regarding its third priority, “people,” Envista continues to advance its culture of continuous improvement, with engagement and talent development showing steady progress.
In terms of solvency, the company is in a good position. This is evident from its zero current debt with cash and cash equivalents of $1.21 billion at the end of 2025. Such underlying financial strength gives Envista strong flexibility amid the ongoing macroeconomic uncertainty. NVST’s net debt to adjusted EBITDA was approximately 0.6X, signaling stability and flexibility, particularly during periods of heightened macroeconomic uncertainty.
Image Source: Zacks Investment Research
Concerns for NVST Stock
Envista’s operations remain vulnerable to global economic conditions, including sustained inflation, increases in interest rates, customer channel inventory realignment and ongoing supply-chain disruptions. The company also maintains a production facility in Israel related to its Alpha-Bio Tech Implant brand and has experienced some volatility in the region.
A Glance at NVST’s Consensus Estimates
Envista’s 2026 and 2027 earnings per share (EPS) are expected to increase 18.5% and 10.5% to $1.41 and $1.55, respectively, year over year. In the past 30 days, the Zacks Consensus Estimate for the company's 2026 EPS has remained unchanged.
Revenues for 2026 are projected to grow 4.5% to $2.84 billion, while those for 2027 are expected to reach $2.95 billion, implying a 3.7% increase.
Other Top MedTech Stocks
Some other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s -0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 22.3% against the industry’s 3.8% decline over the past year.
Phibro Animal Health, sporting a Zacks Rank #1 at present, has an earnings yield of 6.1% compared with the industry’s 2.6% yield. Shares of the company have climbed 130.6% against the industry’s 17.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.2%.
Intuitive Surgical, sporting a Zacks Rank #2 at present, has an earnings yield of 2.1% against the industry’s -0.7% yield. Shares of the company have lost 0.9% compared with the industry’s 39% decline. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Envista Stock Up 42.5% in a Year: What's Driving It?
Key Takeaways
Envista (NVST - Free Report) shares have climbed 42.5% over the past year, showcasing impressive momentum. The stock has outpaced the industry’s 22.5% decline and the S&P 500 composite’s 16.6% gain.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #1 (Strong Buy) company appears to be a solid wealth creator for its investors now.
Headquartered in Brea, CA, Envista was built through the acquisition and integration of more than 25 leading dental businesses and brands over a 15-year period. The company is a global family of more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr. The company offers a comprehensive solution to support implant-based tooth replacements, orthodontic treatments, digital imaging and diagnostics. Envista operates through two segments — Specialty Products & Technologies and Equipment & Consumables.
Key Factors Behind NVST’s Surge
Envista’s share price is trending upward, prompted by strategic acquisitions which complement its current portfolio and broaden it into new and lucrative economic sectors. In line with this, in the first half of 2025, the company closed two small acquisitions, both at favourable EBITDA multiples, which supported its ongoing organic initiatives.
Investors expressed optimism about Envista’s priorities, centered on three areas — growth, operations and people. The fourth quarter of 2025 delivered positive growth across key businesses and all major geographies, supported by a double-digit increase in R&D investment. The company also hosted several high-impact events across geographies and business segments. Envista continues to benefit from the Envista Business System (“EBS”). In 2025, Envista reduced company-wide G&A expenses by 10% year over year, while maintaining its high standards of safety, quality and customer service.
The company also expanded its manufacturing footprint in China with a new site in Suzhou, primarily to support growing local demand. Regarding its third priority, “people,” Envista continues to advance its culture of continuous improvement, with engagement and talent development showing steady progress.
In terms of solvency, the company is in a good position. This is evident from its zero current debt with cash and cash equivalents of $1.21 billion at the end of 2025. Such underlying financial strength gives Envista strong flexibility amid the ongoing macroeconomic uncertainty. NVST’s net debt to adjusted EBITDA was approximately 0.6X, signaling stability and flexibility, particularly during periods of heightened macroeconomic uncertainty.
Image Source: Zacks Investment Research
Concerns for NVST Stock
Envista’s operations remain vulnerable to global economic conditions, including sustained inflation, increases in interest rates, customer channel inventory realignment and ongoing supply-chain disruptions. The company also maintains a production facility in Israel related to its Alpha-Bio Tech Implant brand and has experienced some volatility in the region.
A Glance at NVST’s Consensus Estimates
Envista’s 2026 and 2027 earnings per share (EPS) are expected to increase 18.5% and 10.5% to $1.41 and $1.55, respectively, year over year. In the past 30 days, the Zacks Consensus Estimate for the company's 2026 EPS has remained unchanged.
Revenues for 2026 are projected to grow 4.5% to $2.84 billion, while those for 2027 are expected to reach $2.95 billion, implying a 3.7% increase.
Other Top MedTech Stocks
Some other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s -0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 22.3% against the industry’s 3.8% decline over the past year.
GMED sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Phibro Animal Health, sporting a Zacks Rank #1 at present, has an earnings yield of 6.1% compared with the industry’s 2.6% yield. Shares of the company have climbed 130.6% against the industry’s 17.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.2%.
Intuitive Surgical, sporting a Zacks Rank #2 at present, has an earnings yield of 2.1% against the industry’s -0.7% yield. Shares of the company have lost 0.9% compared with the industry’s 39% decline. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.